Zevra Therapeutics (ZVRA) Assets (2014 - 2026)

Zevra Therapeutics' Assets history runs 13 years deep, the most recent figure standing at $278.6 million for Q1 2026.

• Quarterly Assets rose 61.3% year-over-year to $278.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $278.6 million (up 61.3% YoY) and the FY2025 annual result came in at $284.7 million, up 59.85% from the prior year.
• Assets was $278.6 million for Q1 2026 at Zevra Therapeutics, down from $284.7 million in the prior quarter.
• Across five years, Assets topped out at $284.7 million in Q4 2025 and bottomed at -$426000.0 in Q1 2022.
• A 5-year average of $168.9 million and a median of $161.8 million in 2023 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets slumped 100.47% — and 2025, when it soared 77.47%.
• Zevra Therapeutics' Assets stood at $115.3 million in 2022, then jumped by 49.41% to $172.3 million in 2023, then increased by 3.37% to $178.1 million in 2024, then soared by 59.85% to $284.7 million in 2025, then retreated by 2.16% to $278.6 million in 2026.
• Business Quant data shows ZVRA's Assets at $278.6 million in Q1 2026, $284.7 million in Q4 2025, and $270.1 million in Q3 2025.